Novavax's stock surged 5.02% in pre-market trading on Thursday, indicating strong investor interest ahead of the regular session.
The significant pre-market gain appears to be driven by a positive analyst action. TD Cowen raised its price target on Novavax to $9 from $8, while maintaining a Hold rating on the shares. Such upward revisions in price targets are often viewed by the market as a sign of improving fundamentals or prospects, prompting buying activity.